This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, T. J. Articles by Yang, C. S. Search for Related Content PubMed PubMed Citation Articles by Smith, T. J. Articles by Yang, C. S.

Metabolism of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone in Human Lung and Liver Microsomes and Cytochromes P-450 Expressed in Hepatoma Cells¹

Laboratory for Cancer Research, College of Pharmacy, Rutgers University, Piscataway, New Jersey 08855-0789 [T. J. S., Z. G., C. S. Y.]; Laboratory of Molecular Carcinogenesis, National Cancer Institute, NIH, Bethesda, Maryland 20892 [F. J. G.]; Department of Biochemistry and Center in Molecular Toxicology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146 [F. P. G.]; and Department of Pathology, Medical College of Ohio, Toledo, Ohio 43699 [G. D. S.]

4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a potent tobacco-specific carcinogen in animals, has been linked to tobacco-related cancers in humans. The cytochrome(s) P-450 (P-450) responsible for the metabolic activation of NNK in humans has not been identified. The present work investigated the ability of human lung and liver microsomes and 12 forms of human P-450, expressed in Hep G2 (hepatoma) cells, to metabolize NNK. Of the 12 P-450 forms, P-450 1A2 had the highest activity in catalyzing the conversion of NNK to the keto alcohol, 4-hydroxy-1-(3-pyridyl)-1-butanone. P-450s 2A6, 2B7, 2E1, 2F1, and 3A5 also had measurable activities in the formation of keto alcohol. The apparent K_m and V_max for the formation of keto alcohol in the P-450 1A2-expressed Hep G2 cell lysate were 309 µM and 55 pmol/min/mg protein, respectively. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol, a reductive product, was the major metabolite formed, whereas the formation of keto alcohol and its aldehyde and acid derivatives (all -hydroxylation products) constituted approximately 1% of the initial amount of NNK in P450-expressed Hep G2 cell lysate. A similar metabolite pattern was observed with human lung or liver microsomes. In human lung microsomes, the apparent K_ms for the formation of 4-hydroxy-4-(3-pyridyl)butyric acid, 4-oxo-1-(3-pyridyl)-1-butanone, NNK-N-oxide, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol were 526, 653, 531, and 573 µM, respectively; the formation of keto alcohol was not observed. For human lung microsomes, there was no sex-related difference in NNK metabolism. Carbon monoxide (90% atmosphere) significantly inhibited the metabolism of NNK in human lung and liver microsomes. 7,8-Benzoflavone, an inhibitor of P-450s 1A1 and 1A2, had no effect on NNK metabolism in human lung microsomes but decreased the formation of keto alcohol by 47% in human liver microsomes. Similarly, antibodies against human P-450s 1A2 and 2E1 decreased keto alcohol formation by 42% and 53%, respectively, in human liver microsomes but did not affect NNK metabolism in lung microsomes. Inhibitory antibodies against P-450s 2A1, 2C8, 2D1, or 3A4 had little or no effect on the metabolism of NNK in human liver or lung microsomes. These results demonstrate that human liver and lung microsomes have the capacity to metabolize NNK and that different P-450 forms are responsible for the formation of different metabolites and suggest that other enzymes may be important in the activation of this carcinogen in the human lung.

¹ Supported by NIH Grants CA46535, CA37037, and CA44353; a fellowship from the New Jersey Commission on Cancer Research (89-2050); and National Institute of Environmental Health Services Grants ES-05022 and ES-00267.

² To whom requests for reprints should be addressed, at Laboratory for Cancer Research, College of Pharmacy, Rutgers University, Piscataway, NJ 08855-0789.

Received 10/23/91. Accepted 1/24/92.

This article has been cited by other articles:

				L. E. Sandercock, J. N. Hahn, L. Li, H.A. Luchman, J. L. Giesbrecht, L. A. Peterson, and F. R. Jirik Mgmt deficiency alters the in vivo mutational spectrum of tissues exposed to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) Carcinogenesis, April 1, 2008; 29(4): 866 - 874. [Abstract] [Full Text] [PDF]

				X. Zhang, J. D'Agostino, H. Wu, Q.-Y. Zhang, L. von Weymarn, S. E. Murphy, and X. Ding CYP2A13: Variable Expression and Role in Human Lung Microsomal Metabolic Activation of the Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 570 - 578. [Abstract] [Full Text] [PDF]

				P. J. Brown, L. L. Bedard, K. R. Reid, D. Petsikas, and T. E. Massey Analysis of CYP2A Contributions to Metabolism of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone in Human Peripheral Lung Microsomes Drug Metab. Dispos., November 1, 2007; 35(11): 2086 - 2094. [Abstract] [Full Text] [PDF]

				M. Miyazaki, H. Yamazaki, H. Takeuchi, K. Saoo, M. Yokohira, K.-i. Masumura, T. Nohmi, Y. Funae, K. Imaida, and T. Kamataki Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas Carcinogenesis, November 1, 2005; 26(11): 1947 - 1955. [Abstract] [Full Text] [PDF]

				U. Breyer-Pfaff, H.-J. Martin, M. Ernst, and E. Maser ENANTIOSELECTIVITY OF CARBONYL REDUCTION OF 4-METHYLNITROSAMINO-1-(3-PYRIDYL)-1-BUTANONE BY TISSUE FRACTIONS FROM HUMAN AND RAT AND BY ENZYMES ISOLATED FROM HUMAN LIVER Drug Metab. Dispos., September 1, 2004; 32(9): 915 - 922. [Abstract] [Full Text] [PDF]

				H. Wang, W. Tan, B. Hao, X. Miao, G. Zhou, F. He, and D. Lin Substantial Reduction in Risk of Lung Adenocarcinoma Associated with Genetic Polymorphism in CYP2A13, the Most Active Cytochrome P450 for the Metabolic Activation of Tobacco-Specific Carcinogen NNK Cancer Res., November 15, 2003; 63(22): 8057 - 8061. [Abstract] [Full Text] [PDF]

				G. B. J. Smith, J. R. Bend, L. L. Bedard, K. R. Reid, D. Petsikas, and T. E. Massey BIOTRANSFORMATION OF 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE (NNK) IN PERIPHERAL HUMAN LUNG MICROSOMES Drug Metab. Dispos., September 1, 2003; 31(9): 1134 - 1141. [Abstract] [Full Text] [PDF]

				B. A. Carr, J. Wan, R. N. Hines, and G. S. Yost Characterization of the Human Lung CYP2F1 Gene and Identification of a Novel Lung-specific Binding Motif J. Biol. Chem., April 25, 2003; 278(18): 15473 - 15483. [Abstract] [Full Text] [PDF]

				M. Nakajima, R. Yoshida, N. Shimada, H. Yamazaki, and T. Yokoi Inhibition and Inactivation of Human Cytochrome P450 Isoforms by Phenethyl Isothiocyanate Drug Metab. Dispos., August 1, 2001; 29(8): 1110 - 1113. [Abstract] [Full Text] [PDF]

				M. Vondracek, Z. Xi, P. Larsson, V. Baker, K. Mace, A. Pfeifer, H. Tjalve, M.T. Donato, M.J. Gomez-Lechon, and R. C. Grafstrom Cytochrome P450 expression and related metabolism in human buccal mucosa Carcinogenesis, March 1, 2001; 22(3): 481 - 488. [Abstract] [Full Text] [PDF]

				B. Prokopczyk, N. Trushin, J. Leszczynska, S. E. Waggoner, and K. El-Bayoumy Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, via {{alpha}}-hydroxylation and carbonyl reduction pathways Carcinogenesis, January 1, 2001; 22(1): 107 - 114. [Abstract] [Full Text] [PDF]

				T. Su, Z. Bao, Q.-Y. Zhang, T. J. Smith, J.-Y. Hong, and X. Ding Human Cytochrome P450 CYP2A13: Predominant Expression in the Respiratory Tract and Its High Efficiency Metabolic Activation of a Tobacco-specific Carcinogen, 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone Cancer Res., September 1, 2000; 60(18): 5074 - 5079. [Abstract] [Full Text]

				E. Schrader, K. I. Hirsch-Ernst, E. Scholz, G. F. Kahl, and H. Foth Metabolism of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in Primary Cultures of Rat Alveolar Type II Cells Drug Metab. Dispos., February 1, 2000; 28(2): 180 - 185. [Abstract] [Full Text]

				S. S. Hecht, N. Trushin, S. K. Chhabra, L. M. Anderson, and P. V. Nerurkar Short Communication: Metabolism of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone by Cultured Monkey Lung Explants Drug Metab. Dispos., January 1, 2000; 28(1): 5 - 9. [Abstract] [Full Text]

				S. S. Hecht, C. Chen, L. S. Cook, X.-Y. Li, S. Hallagan, M. M. Madeleine, J. R. Daling, and N. S. Weiss Correspondence re: C. Chen et al., CYP2D6 Genotype and the Incidence of Anal and Vulvar Cancer. Cancer Epidemiol. Biomark. Prev., 8: 317-321, 1999 Cancer Epidemiol. Biomarkers Prev., September 1, 1999; 8(9): 839 - 840. [Full Text]

				G. B.J. Smith, A. Castonguay, P. J. Donnelly, K. R. Reid, D. Petsikas, and T. E. Massey Biotransformation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in freshly isolated human lung cells Carcinogenesis, September 1, 1999; 20(9): 1809 - 1818. [Abstract] [Full Text] [PDF]

				S. S. Hecht Tobacco Smoke Carcinogens and Lung Cancer J Natl Cancer Inst, July 21, 1999; 91(14): 1194 - 1210. [Abstract] [Full Text] [PDF]

				E. L. Code, C. L. Crespi, B. W. Penman, F. J. Gonzalez, T. K. H. Chang, and D. J. Waxman Human Cytochrome P4502B6. Interindividual Hepatic Expression, Substrate Specificity, and Role in Procarcinogen Activation Drug Metab. Dispos., August 1, 1997; 25(8): 985 - 993. [Abstract] [Full Text]

				M. E. Staretz, S. E. Murphy, C. J. Patten, M. G. Nunes, W. Koehl, S. Amin, L. A. Koenig, F. P. Guengerich, and S. S. Hecht Comparative Metabolism of the Tobacco-Related Carcinogens Benzo[a]pyrene, 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone, 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol, and N'-Nitrosonornicotine in Human Hepatic Microsomes Drug Metab. Dispos., February 1, 1997; 25(2): 154 - 162. [Abstract] [Full Text]